Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
An unique and intriguing characteristic of lysergic acid diethylamide (LSD) and LSD-like substances is the recurrence of some of the symptoms which appear during the intoxication, in the absence of recent intake of hallucinogens. Hallucinogen persisting perception disorder (HPPD) is a condition in which the re-experiencing of one or more perceptual symptoms causes significant distress or impairment in social, occupational or other important areas of functioning and may be extremely debilitating. Benzodiazepines are one of the recommended agents for the treatment of HPPD but it is unclear which of them may be more helpful. The goal of our investigation was to assess the efficacy of clonazepam in the treatment of LSD-induced HPPD. Sixteen patients fulfilled entrance criteria. All complained of HPPD with anxiety features for at least 3 months and were drug free at least 3 months. They received clonazepam 2 mg/day for 2 months. Follow-up was continued for 6 months. They were weekly evaluated during the 2 months of clonazepam administration and monthly during the follow-up period using the Clinical Global Impression Scale, a Self-report Scale and Hamilton Anxiety Rating Scale. Patients reported a significant relief and the presence of only mild symptomatology during the clonazepam administration. This improvement was clearly sustained and persisted during a 6-month follow-up period. This study suggests that high potency benzodiazepines like clonazepam, which has serotonergic properties, may be more effective than low-potency benzodiazepines in the treatment of some patients with LSD-induced HPPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Rational Use of Benzodiazepines: When and What to Use
Ashton, H. (1994) · Drugs · doi:10.2165/00003495-199448010-00004 · Cited by 593
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
Aghajanian, G. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(99)00046-6 · Cited by 529 · cited 2×
“The acute effects of LSD seem to be mediated through a 5- HT2 postsynaptic partial agonist activity (Sander-Bush et al., 1988; Marek and Aghajanian, 1996) and the enhancement of glutamatergic transmission (Aghajanian and Marek, 2000).”
BackgroundSchenck, C. H., & Mahowald, M. W. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89493-4 · Cited by 291 · cited 1×
“Among the benzodiazepines, clonazepam seems to have a low abuse potential profile, even in long-term treatment (Pollack, 1987; Schenck and Mahowald, 1996).”
BackgroundBehavior Genetics of Drug Sensitization
Phillips, T. J. (1997) · Critical Reviews™ in Neurobiology · doi:10.1615/critrevneurobiol.v11.i1.20 · Cited by 54 · cited 1×
“Reverse tolerance or LSD sensitization originating after LSD exposure may also explain the continuation of the imagery after the stimulus has been removed (Stahl, 1996; Phillips, 1997).”
BackgroundExacerbation of hallucinogen-persisting perception disorder with risperidone.
Morehead, D. B. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199708000-00020 · Cited by 33
Clonidine treatment for hallucinogen persisting perception disorder.
LERNER, A. G., FINKEL, B., OYFFE, I., MERENZON, I., & SIGAL, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1460 · Cited by 21 · cited 4×
“This study suggests that high potency benzodiazepines like clonazepam, which has serotonergic properties, may be more effective than low-potency benzodiazepines in the treatment of some patients with LSD-induced HPPD. Int Clin Psychopharmacol 18:101–105 c 2003 Lippincott Williams & Wilkins.”
BackgroundInfluentialSelf-citation
Cited by
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
Self-citationOrsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99
“Several studies suggested prescribing clonazepam as an effective treatment in reducing persistent perceptual disturbances (19, 20, 25, 27).”
BackgroundInfluentialDoyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., et al. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2063273 · Cited by 27
Pharmacological Treatment of Hallucinogen Persisting Perception Disorder (HPPD): A Systematic Review
Neven, A., & Blom, J. D. (2025) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000439 · Cited by 4
Metadata
- Authors
- Lerner, A. G., Gelkopf, M., Skladman, I., Rudinski, D., Nachshon, H., & Bleich, A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2003-03
- Volume
- 18
- Issue
- 2
- Pages
- 101-105
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2078583994
- Cited by
- 51
- References
- 6
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. https://app.cochat.ai/papers/10.1097/00004850-200303000-00007
- The paper
- Lerner, A. G., Gelkopf, M., Skladman, I., Rudinski, D., Nachshon, H., & Bleich, A. (2003). Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200303000-00007
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.